JP2018507223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507223A5 JP2018507223A5 JP2017545352A JP2017545352A JP2018507223A5 JP 2018507223 A5 JP2018507223 A5 JP 2018507223A5 JP 2017545352 A JP2017545352 A JP 2017545352A JP 2017545352 A JP2017545352 A JP 2017545352A JP 2018507223 A5 JP2018507223 A5 JP 2018507223A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- disease
- pseudogout
- bronchiectasis
- gout
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 8
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 4
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims 4
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 claims 4
- 201000005569 Gout Diseases 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 4
- 206010063837 Reperfusion injury Diseases 0.000 claims 4
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims 4
- 206010040047 Sepsis Diseases 0.000 claims 4
- 208000002223 abdominal aortic aneurysm Diseases 0.000 claims 4
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 4
- 208000007474 aortic aneurysm Diseases 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 201000009267 bronchiectasis Diseases 0.000 claims 4
- 208000002849 chondrocalcinosis Diseases 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 4
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 229910052805 deuterium Inorganic materials 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 201000004792 malaria Diseases 0.000 claims 2
- -1 methyl- Chemical group 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15157811.9 | 2015-03-05 | ||
| EP15157811 | 2015-03-05 | ||
| PCT/EP2016/054674 WO2016139351A1 (en) | 2015-03-05 | 2016-03-04 | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018507223A JP2018507223A (ja) | 2018-03-15 |
| JP2018507223A5 true JP2018507223A5 (enExample) | 2019-03-14 |
| JP6783426B2 JP6783426B2 (ja) | 2020-11-11 |
Family
ID=52648854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017545352A Active JP6783426B2 (ja) | 2015-03-05 | 2016-03-04 | ジペプチジルペプチダーゼｉ阻害剤としてのペプチジルニトリル化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10479781B2 (enExample) |
| EP (1) | EP3265452B1 (enExample) |
| JP (1) | JP6783426B2 (enExample) |
| AU (1) | AU2016227618B2 (enExample) |
| CA (1) | CA2978234C (enExample) |
| DK (1) | DK3265452T3 (enExample) |
| WO (1) | WO2016139351A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| DK3265452T3 (en) | 2015-03-05 | 2020-06-08 | Neuprozyme Therapeutics ApS | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors |
| FI3758708T3 (fi) | 2018-03-01 | 2025-02-18 | Astrazeneca Ab | (2s)-{(1s)-1-syano-2-[4-(3-metyyli-2-okso-2,3-dihydro-1,3-bentsoksatsol-5-yyli)fenyyli]etyyli}-1,4-oksatsepaani-2-karboksamidia käsittäviä farmaseuttisia koostumuksia |
| KR20210032431A (ko) | 2018-07-17 | 2021-03-24 | 인스메드 인코포레이티드 | 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드 |
| CA3181285A1 (en) | 2020-07-20 | 2022-01-27 | Jessica BASSO | Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions |
| KR20240004691A (ko) * | 2021-04-29 | 2024-01-11 | 인스메드 인코포레이티드 | 낭성 섬유증 치료를 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복사미드 |
| EP4646265A1 (en) | 2023-01-06 | 2025-11-12 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| WO2025162472A1 (en) * | 2024-01-31 | 2025-08-07 | Insmed Incorporated | Linear dipeptidyl peptidase 1 inhibitors and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100098683A (ko) | 2007-12-12 | 2010-09-08 | 아스트라제네카 아베 | 펩티딜 니트릴, 및 디펩티딜 펩티다제 ｉ 억제제로서의 그의 용도 |
| AU2010244218B2 (en) | 2009-05-07 | 2012-07-19 | Astrazeneca Ab | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750 |
| WO2010142985A1 (en) | 2009-06-10 | 2010-12-16 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761 |
| WO2011154677A1 (en) | 2010-06-09 | 2011-12-15 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760 |
| WO2012119941A1 (en) * | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
| WO2012130299A1 (en) | 2011-03-30 | 2012-10-04 | Prozymex A/S | Peptidase inhibitors |
| US8999975B2 (en) | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
| AU2014230814B2 (en) * | 2013-03-14 | 2017-12-21 | Boehringer Ingelheim International Gmbh | Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C |
| IN2013MU02212A (enExample) | 2013-07-01 | 2015-06-12 | Mandar Agashe | |
| DK3044214T3 (da) | 2013-09-09 | 2017-11-13 | Prozymex As | Peptidylnitrilforbindelser som dipeptidylpeptidase-I-inhibitorer |
| DK3265452T3 (en) | 2015-03-05 | 2020-06-08 | Neuprozyme Therapeutics ApS | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors |
-
2016
- 2016-03-04 DK DK16707819.5T patent/DK3265452T3/da active
- 2016-03-04 AU AU2016227618A patent/AU2016227618B2/en active Active
- 2016-03-04 JP JP2017545352A patent/JP6783426B2/ja active Active
- 2016-03-04 EP EP16707819.5A patent/EP3265452B1/en active Active
- 2016-03-04 US US15/554,514 patent/US10479781B2/en active Active
- 2016-03-04 WO PCT/EP2016/054674 patent/WO2016139351A1/en not_active Ceased
- 2016-03-04 CA CA2978234A patent/CA2978234C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016529306A5 (enExample) | ||
| JP2018535967A5 (enExample) | ||
| JP2016525130A5 (enExample) | ||
| JP2019034943A5 (enExample) | ||
| JP2014528403A5 (enExample) | ||
| JP2020532547A5 (enExample) | ||
| JP2017530959A5 (enExample) | ||
| JP2009524691A5 (enExample) | ||
| JP2008512380A5 (enExample) | ||
| JP2022544714A5 (enExample) | ||
| FI3562487T3 (fi) | Metalloentsyymi-inhibiittoriyhdisteitä | |
| JP2019524883A5 (enExample) | ||
| JP2017523225A5 (enExample) | ||
| JP2009524611A5 (ja) | Ｓ１ｐ１受容体アゴニスト、免疫抑制剤および抗炎症剤としての３，５ージ（アリールまたはヘテロアリール）イソキサゾールおよび１，２，４−オキサジアゾール | |
| JP2013523803A5 (enExample) | ||
| JP2008521831A5 (enExample) | ||
| JP2011527332A5 (enExample) | ||
| JP2008505171A5 (enExample) | ||
| JP2017508733A5 (enExample) | ||
| JP2014097964A5 (enExample) | ||
| JP2020502047A5 (enExample) | ||
| JP2017522348A5 (enExample) | ||
| JP2009543795A5 (enExample) | ||
| JP2020520957A5 (enExample) | ||
| JP2010527985A5 (enExample) |